1. bookVolume 69 (2019): Edizione 4 (December 2019)
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Open Access

A modern approach to the treatment of plaque psoriasis

Pubblicato online: 21 Oct 2019
Volume & Edizione: Volume 69 (2019) - Edizione 4 (December 2019)
Pagine: 511 - 523
Accettato: 23 Jun 2019
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. N. Ayala-Fontanez, D. C. Soler and T. S. McCormick, Current knowledge on psoriasis and autoimmune diseases, Psoriasis (Auckl)6 (2016) 7–32; https://doi.org/10.2147/PTT.S6495010.2147/PTT.S64950568313029387591Search in Google Scholar

2. C. E. M. Griffiths, J. M. van der Walt, D. M. Ashcroft, C. Flohr, L. Naldi, T. Nijsten and M. Augustin, The global state of psoriasis disease epidemiology: A workshop report, Br. J. Dermatol.177 (2017) e4–e7; https://doi.org/10.1111/bjd.1561010.1111/bjd.15610560008228555722Search in Google Scholar

3. M. Kaštelan, Psoriasis, Reumatizam64 (2017) 31–36.Search in Google Scholar

4. D. A. Springate, R. Parisi, E. Kontopantelis, D. Reeves, C. E. M. Griffiths and D. M. Ashcroft, Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study, Br. J. Dermatol.176 (2017) 650–658; https://doi.org/10.1111/bjd.1502110.1111/bjd.15021536324127579733Search in Google Scholar

5. P. di Meglio, F. Villanova and F. O. Nestle, Psoriasis, Cold Spring Harb. Perspect. Med.4 (2014) a015354; https://doi.org/10.1101/cshperspect.a01535410.1101/cshperspect.a015354410958025085957Search in Google Scholar

6. M. A. Lowes, M. Suarez-Farinas and J. G. Krueger, Immunology of psoriasis, Ann. Rev. Immunol.32 (2014) 227–255; https://doi.org/10.1146/annurev-immunol-032713-12022510.1146/annurev-immunol-032713-120225422924724655295Search in Google Scholar

7. J. Takeshita, S. Grewal, S. M. Langan, N. N. Mehta, A. Ogdie, A. S. Van Voorhees and J. M. Gefland, Psoriasis and comorbid diseases. Part I. Epidemiology, J. Am. Acad. Dermatol.76 (2017) 377–390; https://doi.org/10.1016/j.jaad.2016.07.06410.1016/j.jaad.2016.07.064573165028212759Search in Google Scholar

8. E. Dauden, S. Castaneda, C. Suarez, J. Garcia Campayo, A. J. Blasco, M. D. Aguilar, C. Ferrandiz, L. Puig and J. L. Sanchez-Carazo, Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis, J. Eur. Acad. Dermatol. Venereol.27 (2013) 1387–1404; https://doi.org/10.1111/jdv.1202410.1111/jdv.1202423134338Search in Google Scholar

9. F. O. Nestle, D. H. Kaplan and J. Barker, Psoriasis, N. Eng. J. Med.361 (2009) 496–509; https://doi.org/10.1056/NEJMra080459510.1056/NEJMra080459519641206Search in Google Scholar

10. Global report on psoriasis, World Health Organization 2016. www.who.intSearch in Google Scholar

11. M. Meštrović, Suvremene spoznaje o etiopatogenezi psorijaze, Sveučilište u Zagrebu, Zagreb 2016.Search in Google Scholar

12. M. Haroon, P. Gallagher and O. FitzGerald, Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis, Ann. Rheum. Dis.74 (2015) 1045–1050; https://doi.org/10.1136/annrheumdis-2013-20485810.1136/annrheumdis-2013-20485824525911Search in Google Scholar

13. C. Conrad and M. Gilliet, Psoriasis: from pathogenesis to targeted therapies, Clin. Rev. Allergy Immunol.54 (2018) 102–113; https://doi.org/10.1007/s12016-018-8668-110.1007/s12016-018-8668-129349534Search in Google Scholar

14. W-H. Boehncke and N. C. Brembilla, Unmet needs in the field of psoriasis: pathogenesis and treatment, Clin. Rev. Allergy Immunol.55 (2018) 295–311; https://doi.org/10.1007/s12016-017-8634-310.1007/s12016-017-8634-328780731Search in Google Scholar

15. S. R. Feldman, Treatment of psoriasis in adults; https://www.uptodate.com/contents/treatment-ofpsoriasis-in-adultsSearch in Google Scholar

16. E. Christophers and U. Mrowietz, Psoriasis, in Braun-Falco’s Dermatology (Eds. Burgdorf, Plewig, Wolf, Landthaller), 3rd ed., Springer, Berlin 2009, pp. 506–526.10.1007/978-3-540-29316-3_36Search in Google Scholar

17. E. C. Siegfried, J. C. Jaworski and A. A. Herbert, Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice, Am. J. Clin. Dermatol.14 (2013) 163–178; https://doi.org/10.1007/s40257-013-0020-110.1007/s40257-013-0020-1366949923703374Search in Google Scholar

18. K. Kragballe and P. C. van de Kerkhof, Consistency of data in six phase III clinical studies of a two compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis, J. Eur. Acad. Dermatol. Venereol20 (2006) 20–39; https://doi.org/10.1111/j.1468-3083.2005.01343.x10.1111/j.1468-3083.2005.01343.x16405606Search in Google Scholar

19. P. Asawanonda and Y. Nateetongrungsak, Methotrexate plus narrowband UVB phototherapy versus narowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study, J. Am. Acad. Dermatol.54 (2006) 1013–1018; https://doi.org/10.1016/j.jaad.2006.01.00410.1016/j.jaad.2006.01.00416713455Search in Google Scholar

20. A. Tanew, A. Guggenbichler, H. Honigsmann, J. M. Geiger and P. Fritsch, Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study, J. Am. Acad. Dermatol.25 (1991) 682–684.Search in Google Scholar

21. M. Kaštelan, N. Puizina Ivić, R. Čeović, Z. Jukić, V. Bulat, E. Simonić, L. Prpić Massari, I. Brajac and G. Krnjević Pezić, Guidelines for the diagnosis and treatment of psoriasis, Liječ. Vjesn.135 (2013) 195–200.Search in Google Scholar

22. A. Nast, L. Amelunxen, M. Augustin, W-H. Boehncke, C. Dressler, M. Gaskins, P. Harle, B. Hoffstadt, J. Klauss, J. Koza, U. Mrowietz, H-M. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, B. Rzany, M. Schlager, G. Schmid-Ott, M. Sebastian, R. Von Kiedrowski and T. Weberschock, S3 Guideline for the treatment of psoriasis vulgaris, update-short version part 1-systemic treatment, JDDG16 (2018) 645–669; https://doi.org/10.1111/ddg.1351610.1111/ddg.1351629750443Search in Google Scholar

23. A. Nast, P. I. Spuls, G. Van der Kraaij, P. Gisondi, C. Paul, A. D. Ormerod, P. Saiag, C. H. Smith, E. Dauden, E. M. de Jong, E. Feist, R. Jobling, M. Maccarone, U. Mrowietz, K. A. Papp, K. Reich, S. Rosumeck, T. Talme, H. B. Thio, P. van der Kerkhof, R. N. Werner and C. Dressler, European S3-Guideline on the systemic treatment of psoriasis vulgaris-update apremilast and secukinumab-EDF in cooperation with EADV and IPC, J. Eur. Acad. Dermatol. Venereol.31 (2017) 1951–1963; https://doi.org/10.1111/jdv.1445410.1111/jdv.1445428895202Search in Google Scholar

24. S. K. Mahil, F. Capon and J. N. Barker, Update on psoriasis immunopathogenesis and targeted immunotheapy, Semin Immunpathol.38 (2016) 11–27 https://doi.org/10.1007/s00281-015-0539-810.1007/s00281-015-0539-8470657926573299Search in Google Scholar

25. P. Rich, M. Gooderham, H. Bachelez, J. Goncalves, R. M. Day, R. Chen and J. Crowley. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult to treat nail and scalp psoriasis: result of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM2), J. Am. Acad. Dermatol.74 (2016) 134–142; https://doi.org/10.1016/j.jaad.2015.09.00110.1016/j.jaad.2015.09.00126549249Search in Google Scholar

26. M. AbuHilal, S. Walsh and N. Shear, Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: A retrospective study, J. Cutan. Med. Surg.20 (2016) 313–316; https://doi.org/10.1177/120347541663132810.1177/120347541663132826848145Search in Google Scholar

27. L. Hsu, B. T. Snodgrass and A. W. Armstrong. Antidrug antibodies in psoriasis: a systematic review, Br. J. Dermatol.170 (2014) 261–273; https://doi.org/10.1111/bjd.1265410.1111/bjd.12654Search in Google Scholar

28. K. Papp, H. Bachelez, A Constanzo, P. Foley, M. Gooderham, P. Kaur, J. Narbutt, S. Philipp, L. Spelman, J. Weglowska, N. Zhang and B. Strober, Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter phase III study, J. Am. Acad. Dermatol.76 (2017) 1093–1102; https://doi.org/10.1016/j.jaad.2016.12.01410.1016/j.jaad.2016.12.014Search in Google Scholar

29. T. Bito, R. Nishikawa, M. Hatakeyama, A. Kikusawa, H. Kanki, H. Nagai, Y. Sarayama, T. Ikeda, H. Yoshizaki, H. Seto, A. Adachi, T. Horikawa, M. Oka and C. Nishigiri, Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis, Br. J. Dermatol.170 (2014) 922–929; https://doi.org/10.1111/bjd.12791.10.1111/bjd.12791Search in Google Scholar

30. K. K. Jorgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, C. Mork, J. Jahnsen and T. K. Kvien, Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non inferiority trial, Lancet389 (2017) 2304–2316 https://doi.org/10.1016/S0140-6736(17)30068-510.1016/S0140-6736(17)30068-5Search in Google Scholar

31. K. Reich, A. D. Burden, J. N. Eaton and N. S. Hawkins, Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials, Br. J. Dermatol.166 (2012) 179–188; https://doi.org/10.1111/j.1365-2133.2011.10583.x10.1111/j.1365-2133.2011.10583.x21910698Search in Google Scholar

32. C. Ryan, C. L. Leonardi, J. G. Krueger A. B. Kimball, B. E. Strober, K. B. Gordon, R. G. Langley, J. A. de Lemos, Y. Daud, D. Blankenship, S. Kazi, D. H. Kaplan, V. E. Friedewald and A. Menter, Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials, JAMA306 (2011) 864–871; https://doi.org/10.1001/jama.2011.121110.1001/jama.2011.121121862748Search in Google Scholar

33. K. A. Papp, C. E. Griffiths, K. Gordon, M. Lebwohl, P. O. Szapary, Y. Wasfi, D. Chan, M. C. Hsu, V. Ho, P. D. Ghislain, B. Strober, K. Reich and PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators, Long-term safety of ustekinumab in patients with moderate to severe psoriasis: final results from 5 years of follow-up, Br. J. Dermatol.168 (2013) 844–854; https://doi.org/10.1111/bjd.1221410.1111/bjd.1221423301632Search in Google Scholar

34. A. Blauvelt, Safety of secukinumab in the treatment of psoriasis, Expert Opin. Drug Saf.15 (2016) 1413–1420; https://doi.org/10.1080/14740338.2016.122192310.1080/14740338.2016.122192327545070Search in Google Scholar

35. K. B. Gordon, A. Blauvelt, P. Foley, M. Song, Y. Wasfi, B. Randazzo, Y. K. Shen, Y. You and C. E. M. Griffiths, Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies, Br. J. Dermatol.178 (2018) 132–139; https://doi.org/10.1111/bjd.1600810.1111/bjd.1600828940259Search in Google Scholar

36. K. Papp, D. Thaci, K. Reich, A. Blauwelt, E. Riedl, R. G. Langley, J. G. Krueger, A. B. Gottlieb, H. Nakagawa, E. P. Bowman, A. Mehta, Q. Li, Y. Zhou and R. Shames. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial, Br. J. Dermatol.173 (2015) 930–939. https://doi.org/10.1111/bjd.1393210.1111/bjd.1393226042589Search in Google Scholar

37. K. A. Papp, A. Blauvelt, M. Bukhalo, M. Gooderham, J. G. Krueger, J. P. Lacour, A. Menter, S. Philipp, H. Sofen, S. Tyring, B. R. Berner, S. Visvanathan, C. Pamulapati, N. Bennett, M. Flack, P. Scholl and S. J. Padula, Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis, N. Eng. J. Med.376 (2017) 1551–1560; https://doi.org/10.1056/NEJMoa160701710.1056/NEJMoa160701728423301Search in Google Scholar

38. M. Amin, D. J. No, A. Egeberg and J. J. Wu, Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say? Am J. Clin. Dermatol.19 (2018) 1–13; https://doi.org/10.1007/s40257-017-0328-310.1007/s40257-017-0328-329080066Search in Google Scholar

39. K. Ronholt and L. Iversen, Old and new biological therapies for psoriasis, Int. J. Mol. Sci.18 (2017) E2297; https://doi.org/103390/ijms18112297Search in Google Scholar

40. U. Mrowietz, Implementing treatment goals for successful long-term management of psoriasis, J. Eur. Acad. Dermatol. Venereol26 (2012) 12–20; https://doi.org/10.1111/j.1468-3083.2011.04411.x10.1111/j.1468-3083.2011.04411.x22356631Search in Google Scholar

41. A. Osmola-Mankowska, E. Teresiak-Mikolajczak, M. Skrzypczak-Zielinska and Z. Adamski, Genetic polymorphism in psoriasis and its meaning for the treatment efficacy in the future, Postepy Dermatol. Alergol.35 (2018) 331–337; https://doi.org/10.5114/ada.2018.77Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo